Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01337089




Registration number
NCT01337089
Ethics application status
Date submitted
12/04/2011
Date registered
18/04/2011
Date last updated
12/04/2023

Titles & IDs
Public title
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Scientific title
A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Secondary ID [1] 0 0
2009-016529-32
Secondary ID [2] 0 0
GWCA0999
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pain 0 0
Advanced Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Any cancer

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Experimental: Non-comparative, open-label Nabiximols - Nabiximols was self-administered by participants as a 100 microliter (µL) oromucosal spray, in the morning and evening, up to a maximum of 10 sprays per day for 6 months. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligrams \[mg\]/milliliter \[mL\]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Each 100 µL actuation delivered 2.7 mg THC and 2.5 mg CBD.
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percent Of Participants With Treatment-emergent Adverse Events
Timepoint [1] 0 0
Baseline, Day 183
Secondary outcome [1] 0 0
Change From Baseline In Mean NRS Average Pain During The Last Period
Timepoint [1] 0 0
Baseline, Last Period (Days 156-183) or last 27 days of treatment
Secondary outcome [2] 0 0
Change From Baseline In Mean Sleep Disruption NRS During The Last Period
Timepoint [2] 0 0
Baseline, Last Period (Days 156-183) or last 27 days of treatment
Secondary outcome [3] 0 0
Patient Satisfaction Questionnaire At Last Visit (Up To Day 183)
Timepoint [3] 0 0
Last Visit (up to Day 183)
Secondary outcome [4] 0 0
Change From Baseline In NRS Constipation At Last Visit (Up To Day 183)
Timepoint [4] 0 0
Baseline, Last Visit (up to Day 183)

Eligibility
Key inclusion criteria
* Participant had completed the parent study within the last seven days
* Willing and able to give written informed consent
* Willing and able to comply with all study requirements
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* The participant was using cannabis or cannabinoid based medications, other than the parent study investigational medicinal product (IMP), and was unwilling to abstain for the duration of the study
* Any history or immediate family history of schizophrenia, other psychotic illness, severe personality disorder or other significant psychiatric disorder other than depression associated with their underlying condition
* Any known or suspected history of a substance abuse/dependence disorder (including opiate abuse/dependence prior to the diagnosis of cancer), current heavy alcohol consumption (more than 60 grams [g] of pure alcohol per day for men, and more than 40 g of pure alcohol per day for women), current use of an illicit drug or current non-prescribed use of any prescription drug
* Had poorly controlled epilepsy or recurrent seizures (for example, one or more seizure during the last year)
* Had experienced myocardial infarction or clinically significant cardiac dysfunction within the last 12 months or had a cardiac disorder that, in the opinion of the investigator would have put the participant at risk of a clinically significant arrhythmia or myocardial infarction
* Had significantly impaired renal function
* Had significantly impaired hepatic function at the "end of treatment" visit of the parent study
* Female participants of child-bearing potential and male participants whose partner was of child-bearing potential, unless willing to ensure that they or their partner used effective contraception, for example, oral contraception, double barrier, intra-uterine device, during the study and for 3 months thereafter (however, a male condom should not have been used in conjunction with a female condom as this may not have proven effective)

Study design
Purpose of the study
Treatment
Allocation to intervention
NA
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
19/01/2011
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
27/01/2016
Sample size
Target
Accrual to date
Final
660
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Parkville
Recruitment postcode(s) [1] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Kentucky
Country [7] 0 0
United States of America
State/province [7] 0 0
Louisiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Minnesota
Country [9] 0 0
United States of America
State/province [9] 0 0
Missouri
Country [10] 0 0
United States of America
State/province [10] 0 0
Montana
Country [11] 0 0
United States of America
State/province [11] 0 0
New Jersey
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
North Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Ohio
Country [15] 0 0
United States of America
State/province [15] 0 0
Pennsylvania
Country [16] 0 0
United States of America
State/province [16] 0 0
Texas
Country [17] 0 0
United States of America
State/province [17] 0 0
Utah
Country [18] 0 0
United States of America
State/province [18] 0 0
Washington
Country [19] 0 0
Belgium
State/province [19] 0 0
Bruxelles
Country [20] 0 0
Bulgaria
State/province [20] 0 0
Gabrovo
Country [21] 0 0
Bulgaria
State/province [21] 0 0
Varna
Country [22] 0 0
Bulgaria
State/province [22] 0 0
Vratsa
Country [23] 0 0
Czechia
State/province [23] 0 0
Benešov
Country [24] 0 0
Czechia
State/province [24] 0 0
Jablonec Nad Nisou
Country [25] 0 0
Czechia
State/province [25] 0 0
Most
Country [26] 0 0
Czechia
State/province [26] 0 0
Nová Ves Pod Pleší
Country [27] 0 0
Czechia
State/province [27] 0 0
Ostrava
Country [28] 0 0
Czechia
State/province [28] 0 0
Plzen
Country [29] 0 0
Czechia
State/province [29] 0 0
Sokolov
Country [30] 0 0
Czechia
State/province [30] 0 0
Teplice
Country [31] 0 0
Czechia
State/province [31] 0 0
Ceské Budejovice
Country [32] 0 0
Germany
State/province [32] 0 0
Berlin
Country [33] 0 0
Germany
State/province [33] 0 0
Frankfurt
Country [34] 0 0
Germany
State/province [34] 0 0
Jena
Country [35] 0 0
Germany
State/province [35] 0 0
Lunen
Country [36] 0 0
Germany
State/province [36] 0 0
Stadtroda
Country [37] 0 0
Germany
State/province [37] 0 0
Wetzlar
Country [38] 0 0
Germany
State/province [38] 0 0
Wiesbaden
Country [39] 0 0
Hungary
State/province [39] 0 0
Deszk
Country [40] 0 0
Hungary
State/province [40] 0 0
Komarom
Country [41] 0 0
Hungary
State/province [41] 0 0
Miskolc
Country [42] 0 0
Hungary
State/province [42] 0 0
Nyíregyháza
Country [43] 0 0
Hungary
State/province [43] 0 0
Szekszard
Country [44] 0 0
Hungary
State/province [44] 0 0
Szikszo
Country [45] 0 0
Israel
State/province [45] 0 0
Beer Sheva
Country [46] 0 0
Israel
State/province [46] 0 0
Haifa
Country [47] 0 0
Israel
State/province [47] 0 0
Ramat Gan
Country [48] 0 0
Israel
State/province [48] 0 0
Zerifin
Country [49] 0 0
Italy
State/province [49] 0 0
Garbagnate Milanese
Country [50] 0 0
Italy
State/province [50] 0 0
Piacenza
Country [51] 0 0
Italy
State/province [51] 0 0
Torino
Country [52] 0 0
Latvia
State/province [52] 0 0
Riga
Country [53] 0 0
Latvia
State/province [53] 0 0
Rezekne
Country [54] 0 0
Lithuania
State/province [54] 0 0
Klaipeda
Country [55] 0 0
Lithuania
State/province [55] 0 0
Siauliai
Country [56] 0 0
Lithuania
State/province [56] 0 0
Vilnius
Country [57] 0 0
Mexico
State/province [57] 0 0
Chihuahua
Country [58] 0 0
Mexico
State/province [58] 0 0
Distrito Federal
Country [59] 0 0
Poland
State/province [59] 0 0
Bialystok
Country [60] 0 0
Poland
State/province [60] 0 0
Bielsko-Biala
Country [61] 0 0
Poland
State/province [61] 0 0
Bydgoszcz
Country [62] 0 0
Poland
State/province [62] 0 0
Czeladz
Country [63] 0 0
Poland
State/province [63] 0 0
Czestochowa
Country [64] 0 0
Poland
State/province [64] 0 0
Dzialdowo
Country [65] 0 0
Poland
State/province [65] 0 0
Gdansk
Country [66] 0 0
Poland
State/province [66] 0 0
Gliwice
Country [67] 0 0
Poland
State/province [67] 0 0
Klodzko
Country [68] 0 0
Poland
State/province [68] 0 0
Opole
Country [69] 0 0
Poland
State/province [69] 0 0
Ostrowiec Swietokrzyski
Country [70] 0 0
Poland
State/province [70] 0 0
Poznan
Country [71] 0 0
Poland
State/province [71] 0 0
Warszawa
Country [72] 0 0
Poland
State/province [72] 0 0
Wloclawek
Country [73] 0 0
Puerto Rico
State/province [73] 0 0
Ponce
Country [74] 0 0
Puerto Rico
State/province [74] 0 0
San Juan
Country [75] 0 0
Romania
State/province [75] 0 0
Baia Mare
Country [76] 0 0
Romania
State/province [76] 0 0
Braila
Country [77] 0 0
Romania
State/province [77] 0 0
Bucuresti
Country [78] 0 0
Romania
State/province [78] 0 0
Cluj-Napoca
Country [79] 0 0
Romania
State/province [79] 0 0
Constanta
Country [80] 0 0
Romania
State/province [80] 0 0
Craiova
Country [81] 0 0
Romania
State/province [81] 0 0
Focsani
Country [82] 0 0
Romania
State/province [82] 0 0
Iasi
Country [83] 0 0
Romania
State/province [83] 0 0
Oradea
Country [84] 0 0
Romania
State/province [84] 0 0
Satu Mare
Country [85] 0 0
Romania
State/province [85] 0 0
Sibiu
Country [86] 0 0
Romania
State/province [86] 0 0
Suceava
Country [87] 0 0
Romania
State/province [87] 0 0
Târgoviste
Country [88] 0 0
Spain
State/province [88] 0 0
Granada
Country [89] 0 0
Taiwan
State/province [89] 0 0
Taichung
Country [90] 0 0
Taiwan
State/province [90] 0 0
Tainan City
Country [91] 0 0
United Kingdom
State/province [91] 0 0
Bury Saint Edmunds
Country [92] 0 0
United Kingdom
State/province [92] 0 0
Bury
Country [93] 0 0
United Kingdom
State/province [93] 0 0
Cheltenham
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Crumpsall
Country [95] 0 0
United Kingdom
State/province [95] 0 0
Edinburgh
Country [96] 0 0
United Kingdom
State/province [96] 0 0
Gorleston-on-Sea
Country [97] 0 0
United Kingdom
State/province [97] 0 0
Leeds
Country [98] 0 0
United Kingdom
State/province [98] 0 0
Manchester
Country [99] 0 0
United Kingdom
State/province [99] 0 0
Norwich
Country [100] 0 0
United Kingdom
State/province [100] 0 0
Plymouth
Country [101] 0 0
United Kingdom
State/province [101] 0 0
Weston-super-Mare
Country [102] 0 0
United Kingdom
State/province [102] 0 0
Withington

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Jazz Pharmaceuticals
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Otsuka Pharmaceutical Development & Commercialization, Inc.
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT01337089